Related Experiment Video
Updated: May 12, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma
Kieron Dunleavy1, Cliona Grant, Wyndham H Wilson
1Metabolism Branch, National Cancer Institute, Building 10, Room 4N-115, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Therapeutic Advances in Hematology
|April 24, 2013
Summary
Diffuse large B-cell lymphoma (DLBCL) is now recognized as three molecular subtypes: germinal center B-cell like (GCB), activated B-cell like (ABC), and primary mediastinal B-cell lymphoma (PMBL). Each subtype has distinct oncogenic drivers and potential therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) was historically viewed as a singular disease.
- Recent advancements reveal at least three distinct molecular subtypes of DLBCL.
Purpose of the Study:
- To delineate the molecular subtypes of DLBCL: GCB, ABC, and PMBL.
- To identify distinct oncogenic activation mechanisms and potential therapeutic targets for each subtype.
Main Methods:
- Gene expression profiling was utilized to classify DLBCL into molecular subtypes.
- Analysis of specific molecular pathways and factors implicated in each subtype's pathogenesis.
Main Results:
- GCB DLBCL subtypes involve BCL6, a factor in tumor survival and treatment resistance.
- ABC DLBCL subtypes exhibit high expression of NF-κB/Rel pathway targets.
- PMBL shares molecular features with Hodgkin lymphoma and may benefit from specific therapeutic strategies.
Conclusions:
- DLBCL heterogeneity necessitates subtype-specific therapeutic strategies.
- Targeting BCL6, NF-κB, Janus kinases, MYC, and BCL2 are promising avenues for DLBCL treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...